KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Operating Expenses: 2009-2024

Historic Operating Expenses for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $774.3 million.

  • Pacira BioSciences' Operating Expenses fell 43.80% to $173.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $675.2 million, marking a year-over-year decrease of 11.14%. This contributed to the annual value of $774.3 million for FY2024, which is 31.85% up from last year.
  • Per Pacira BioSciences' latest filing, its Operating Expenses stood at $774.3 million for FY2024, which was up 31.85% from $587.3 million recorded in FY2023.
  • Pacira BioSciences' 5-year Operating Expenses high stood at $774.3 million for FY2024, and its period low was $383.3 million during FY2020.
  • Over the past 3 years, Pacira BioSciences' median Operating Expenses value was $606.8 million (recorded in 2022), while the average stood at $656.1 million.
  • Per our database at Business Quant, Pacira BioSciences' Operating Expenses fell by 6.64% in 2020 and then spiked by 34.36% in 2022.
  • Yearly analysis of 5 years shows Pacira BioSciences' Operating Expenses stood at $383.3 million in 2020, then climbed by 17.82% to $451.6 million in 2021, then spiked by 34.36% to $606.8 million in 2022, then fell by 3.21% to $587.3 million in 2023, then skyrocketed by 31.85% to $774.3 million in 2024.